Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.53 |
| ▸ | CASP1 | P29466 | 2/20 | 0.53 |
| ▸ | CASP7 | P55210 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | RYR2 | Q92736 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29978912 | 1.00 | ALDH1A1 (0.60) | ALDH1A1LMNAALOX15HSD17B10KDM4E | |
| SCHEMBL3328395 | 0.92 | ALDH1A1 (0.58) | ALDH1A1LMNAALOX15HSD17B10KDM4E | |
| SCHEMBL22226391 | 0.90 | ALDH1A1 (0.51) | ALDH1A1LMNAALOX15HSD17B10KDM4E | |
| SCHEMBL28765816 | 0.85 | ALDH1A1 (0.63) | ALDH1A1LMNAALOX15HSD17B10KDM4E | |
| SCHEMBL1997553 | 0.82 | HDAC1 (0.46) | ALDH1A1LMNAPOLBHDAC1HDAC8 | |
| SCHEMBL1238568 | 0.81 | HTT (0.56) | ALDH1A1LMNAHSD17B10KDM4EPOLB | |
| SCHEMBL2363066 | 0.81 | ALDH1A1 (0.47) | ALDH1A1LMNAHSD17B10POLBHTT | |
| SCHEMBL3324598 | 0.79 | LMNA (0.76) | ALDH1A1LMNAALOX15HSD17B10KDM4E | |
| SCHEMBL1997763 | 0.79 | HDAC1 (0.46) | ALDH1A1LMNAPOLBHTTHDAC1 | |
| SCHEMBL1995585 | 0.79 | ALDH1A1 (0.53) | ALDH1A1LMNAALOX15HSD17B10KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4384268-B1 | SMALL MOLECULE UREA DERIVATIVES AS STING ANTAGONISTS | CURADEV PHARMA PVT LTD (IN) | 2026-03-18 | — | — | EP | disclosed |
| US-20240360119-A1 | SMALL MOLECULE UREA DERIVATIVES AS STING ANTAGONISTS | CURADEV PHARMA PVT. LTD. (IN) | 2024-10-31 | — | — | US | disclosed |
| EP-4384267-A1 | SMALL MOLECULE STING ANTAGONISTS | Curadev Pharma Pvt. Ltd. (IN) | 2024-06-19 | — | — | EP | disclosed |
| EP-4384268-A1 | SMALL MOLECULE UREA DERIVATIVES AS STING ANTAGONISTS | Curadev Pharma Pvt. Ltd. (IN) | 2024-06-19 | — | — | EP | disclosed |
| CN-118159535-A | Small molecule STING antagonists | 库拉德夫制药私人有限公司 | 2024-06-07 | — | — | CN | disclosed |
| CN-118019738-A | Small molecule urea derivatives as STING antagonists | 库拉德夫制药私人有限公司 | 2024-05-10 | — | — | CN | disclosed |
| US-20230124361-A1 | SMALL MOLECULE STING ANTAGONISTS | CURADEV PHARMA PVT. LTD. (IN) | 2023-04-20 | — | — | US | disclosed |
| US-20230124361-A1 | SMALL MOLECULE STING ANTAGONISTS | CURADEV PHARMA PVT. LTD. (IN) | 2023-04-20 | — | — | US | disclosed |
| WO-2023017452-A1 | SMALL MOLECULE UREA DERIVATIVES AS STING ANTAGONISTS | CURADEV PHARMA PVT. LTD. (IN) | 2023-02-16 | — | — | WO | disclosed |
| WO-2023017451-A1 | SMALL MOLECULE STING ANTAGONISTS | CURADEV PHARMA PVT. LTD. (IN) | 2023-02-16 | — | — | WO | disclosed |
| US-7696200-B2 | Bicyclic sulfonamide derivatives which are L-CPT1 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2010-04-13 | — | — | US | disclosed |
| US-20090075973-A1 | BENZO-FUSED HETEROCYCLES | CARA THERAPEUTICS, INC. (US) | 2009-03-19 | — | — | US | disclosed |
| US-20090075973-A1 | BENZO-FUSED HETEROCYCLES | CARA THERAPEUTICS, INC. (US) | 2009-03-19 | — | — | US | disclosed |
| US-20090075973-A1 | BENZO-FUSED HETEROCYCLES | CARA THERAPEUTICS, INC. (US) | 2009-03-19 | — | — | US | disclosed |
| WO-2009035997-A2 | BENZO-FUSED HETEROCYCLES | CARA THERAPEUTICS, INC. (US) | 2009-03-19 | — | — | WO | disclosed |
| WO-2009035997-A2 | BENZO-FUSED HETEROCYCLES | CARA THERAPEUTICS, INC. (US) | 2009-03-19 | — | — | WO | disclosed |
| EP-1996563-A1 | HETEROBICYCLIC SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF DIABETES | F.HOFFMANN-LA ROCHE AG (CH) | 2008-12-03 | — | — | EP | disclosed |
| WO-2007093507-A1 | HETEROBICYCLIC SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF DIABETES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-23 | — | — | WO | disclosed |
| US-20070191603-A1 | Novel bicyclic sulfonamide derivatives which are L-CPT1 inhibitors | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2007-08-16 | — | — | US | disclosed |
| EP-1031572-A1 | PYRIDYLPYRROLE DERIVATIVES | Sankyo Company Limited (JP) | 2000-08-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240360119-A1 | SMALL MOLECULE UREA DERIVATIVES AS STING ANTAGONISTS | STING1, CGAS, SSB | ALDH1A1 3165/4885LMNA 1842/4885ALOX15 1004/4885 |
| US-20090075973-A1 | BENZO-FUSED HETEROCYCLES | CNR1, CNR2, TRPV1 | ALDH1A1 1422/4885LMNA 3328/4885ALOX15 362/4885 |
| US-20230124361-A1 | SMALL MOLECULE STING ANTAGONISTS | STING1, CGAS, MAVS | ALDH1A1 3672/4885LMNA 2127/4885ALOX15 366/4885 |
| US-20070191603-A1 | Novel bicyclic sulfonamide derivatives which are L-CPT1 inhibitors | CPT1A, CPT1B, CPT2 | ALDH1A1 324/4885LMNA 3212/4885ALOX15 1121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.